Supplementing probiotics reduces asthma symptoms by regulating the gut microbiome and serum metabolome

As a common chronic inflammatory respiratory disease, asthma has a high morbidity and mortality rate worldwide. It affects more than 330 million children and adults. It is estimated that the number of patients will increase to 400 million by 2025 . Recently, the potential impact of the human microbiota in the pathogenesis of asthma and its relationship with the disease phenotype has received special attention . Probiotics can regulate the host's intestinal microbiota and its synthesis/release of certain active compounds, and are often used as an adjuvant therapy . There is a clear connection between the exacerbation of asthma and the host microbiota, especially the gut microbiota, but how they affect asthma symptoms and serum metabolites is still largely unknown . Therefore, the purpose of this test is to study the auxiliary effect of probiotic combination drugs in the control of asthma . A total of 58 subjects were recruited in the study (29 in the probiotic group and 26 in the placebo group), and a randomized, double-blind, placebo-controlled method was used for a 6-month clinical trial . Subjects in the probiotic group used Symbic and Bifidobacterium lactis Probio-M8 (2g; 3x10 10 CFU/day) daily, and the placebo group used Symbic and the same amount of placebo daily . The results found that during the intervention period, compared with placebo, subjects in the probiotic group had significantly lower alveolar nitric oxide concentration (CaNo) and exhaled nitric oxide concentration (FeNO), significantly improved asthma control (ACT) scores, and continued treatment After 3 months, the improvement effect was more significant; after 3 months of taking probiotics, the content of animal Bifidobacterium and Bifidobacterium longum in the intestines of subjects in the probiotic group increased significantly; the probiotic group had a higher diversity of microbiota (SGBs) are involved in the synthesis of butyric acid and the degradation of tryptophan. The content of docosatetraenoic acid, lactoylethanolamide, and sphingomyelin in the intestine is significantly higher than that in the placebo group . Shows that Probio-M8 promotes specific biologically active metabolites and related pathways by regulating the intestinal flora . In addition, after 3 months of treatment, the intake of Probio-M8 significantly changed the serum metabolomics. After the intervention of probiotics, the levels of metabolites such as dodecanoic acid, enterodiol, tryptophan and sphingomyelin in the blood increased significantly. , These metabolites can inhibit the signal pathway to play an anti-inflammatory effect and participate in the immune response . In summary, Probio-M8 improves the bioactive metabolic potential of intestinal microbes and serum metabolites by regulating the intestinal flora, promotes the secretion and synthesis of some key biologically active compounds in the intestine and blood, and directly regulates the intestine through the systemic circulation system- Lung axis, thereby effectively alleviating small airway inflammation and improving the clinical symptoms of asthma patients . The research was published in " Microbiology Spectrum ", a JCR area 2 magazine of the Chinese Academy of Sciences in October 2021. The first author: Liu Ailing, PhD students Ma Teng, Jin Hao, Xu Ning; Corresponding author: Researcher Sun Zhihong (Impact Factor: IF=7. 171) . Original link: https://doi. org/10. 1128/Spectrum. 00859-21   Disclaimer: This article only represents the author's personal views and has nothing to do with China Probiotics. com . The originality and the text and content stated in the article have not been verified by this site. This site does not make any guarantee or commitment to the authenticity, completeness, and timeliness of this article, all or part of the content, and the text. Please readers for reference only, and please Verify the relevant content yourself .   Copyright Notice 1. Some of the reprinted articles on this site are not original, and the copyright and liability belong to the original author . 2. All reprinted articles, links and pictures on this website are for the purpose of conveying more information, and clearly indicate the source and author. Media or individuals who do not want to be reprinted can contact us for infringement information that can provide sufficient evidence , Bio149 will be deleted within 12 hours after confirmation . 3. Users are welcome to post original articles to 86371366@qq. com, and publish them to the homepage after review. The copyright and liability belong to the sender .

　　As a common chronic inflammatory respiratory disease, asthma has a high morbidity and mortality rate worldwide.
It affects more than 330 million children and adults.
It is estimated that the number of patients will increase to 400 million by 2025
.
Recently, the potential impact of the human microbiota in the pathogenesis of asthma and its relationship with the disease phenotype has received special attention
.
Probiotics can regulate the host's intestinal microbiota and its synthesis/release of certain active compounds, and are often used as an adjuvant therapy
.
There is a clear connection between the exacerbation of asthma and the host microbiota, especially the gut microbiota, but how they affect asthma symptoms and serum metabolites is still largely unknown
.
Therefore, the purpose of this test is to study the auxiliary effect of probiotic combination drugs in the control of asthma
.


　　A total of 58 subjects were recruited in the study (29 in the probiotic group and 26 in the placebo group), and a randomized, double-blind, placebo-controlled method was used for a 6-month clinical trial
.
Subjects in the probiotic group used Symbic and Bifidobacterium lactis Probio-M8 (2g; 3x10 ¹⁰ CFU/day) daily, and the placebo group used Symbic and the same amount of placebo daily
.
The results found that during the intervention period, compared with placebo, subjects in the probiotic group had significantly lower alveolar nitric oxide concentration (CaNo) and exhaled nitric oxide concentration (FeNO), significantly improved asthma control (ACT) scores, and continued treatment After 3 months, the improvement effect was more significant; after 3 months of taking probiotics, the content of animal Bifidobacterium and Bifidobacterium longum in the intestines of subjects in the probiotic group increased significantly; the probiotic group had a higher diversity of microbiota (SGBs) are involved in the synthesis of butyric acid and the degradation of tryptophan.
The content of docosatetraenoic acid, lactoylethanolamide, and sphingomyelin in the intestine is significantly higher than that in the placebo group
.
Shows that Probio-M8 promotes specific biologically active metabolites and related pathways by regulating the intestinal flora
.
In addition, after 3 months of treatment, the intake of Probio-M8 significantly changed the serum metabolomics.
After the intervention of probiotics, the levels of metabolites such as dodecanoic acid, enterodiol, tryptophan and sphingomyelin in the blood increased significantly.
, These metabolites can inhibit the signal pathway to play an anti-inflammatory effect and participate in the immune response
.
In summary, Probio-M8 improves the bioactive metabolic potential of intestinal microbes and serum metabolites by regulating the intestinal flora, promotes the secretion and synthesis of some key biologically active compounds in the intestine and blood, and directly regulates the intestine through the systemic circulation system- Lung axis, thereby effectively alleviating small airway inflammation and improving the clinical symptoms of asthma patients
.


　　The research was published in " Microbiology Spectrum ", a JCR area 2 magazine of the Chinese Academy of Sciences in October 2021.
The first author: Liu Ailing, PhD students Ma Teng, Jin Hao, Xu Ning; Corresponding author: Researcher Sun Zhihong (Impact Factor: IF=7.
171)
.


Original link: https://doi.
org/10.
1128/Spectrum.
00859-21

---

　　As a common chronic inflammatory respiratory disease, asthma has a high morbidity and mortality rate worldwide.
It affects more than 330 million children and adults.
It is estimated that the number of patients will increase to 400 million by 2025
.
Recently, the potential impact of the human microbiota in the pathogenesis of asthma and its relationship with the disease phenotype has received special attention
.
Probiotics can regulate the host's intestinal microbiota and its synthesis/release of certain active compounds, and are often used as an adjuvant therapy
.
There is a clear connection between the exacerbation of asthma and the host microbiota, especially the gut microbiota, but how they affect asthma symptoms and serum metabolites is still largely unknown
.
Therefore, the purpose of this test is to study the auxiliary effect of probiotic combination drugs in the control of asthma
.


　　A total of 58 subjects were recruited in the study (29 in the probiotic group and 26 in the placebo group), and a randomized, double-blind, placebo-controlled method was used for a 6-month clinical trial
.
Subjects in the probiotic group used Symbic and Bifidobacterium lactis Probio-M8 (2g; 3x10 ¹⁰ CFU/day) daily, and the placebo group used Symbic and the same amount of placebo daily
.
The results found that during the intervention period, compared with placebo, subjects in the probiotic group had significantly lower alveolar nitric oxide concentration (CaNo) and exhaled nitric oxide concentration (FeNO), significantly improved asthma control (ACT) scores, and continued treatment After 3 months, the improvement effect was more significant; after 3 months of taking probiotics, the content of animal Bifidobacterium and Bifidobacterium longum in the intestines of subjects in the probiotic group increased significantly; the probiotic group had a higher diversity of microbiota (SGBs) are involved in the synthesis of butyric acid and the degradation of tryptophan.
The content of docosatetraenoic acid, lactoylethanolamide, and sphingomyelin in the intestine is significantly higher than that in the placebo group
.
Shows that Probio-M8 promotes specific biologically active metabolites and related pathways by regulating the intestinal flora
.
In addition, after 3 months of treatment, the intake of Probio-M8 significantly changed the serum metabolomics.
After the intervention of probiotics, the levels of metabolites such as dodecanoic acid, enterodiol, tryptophan and sphingomyelin in the blood increased significantly.
, These metabolites can inhibit the signal pathway to play an anti-inflammatory effect and participate in the immune response
.
In summary, Probio-M8 improves the bioactive metabolic potential of intestinal microbes and serum metabolites by regulating the intestinal flora, promotes the secretion and synthesis of some key biologically active compounds in the intestine and blood, and directly regulates the intestine through the systemic circulation system- Lung axis, thereby effectively alleviating small airway inflammation and improving the clinical symptoms of asthma patients
.


　　The research was published in " Microbiology Spectrum ", a JCR area 2 magazine of the Chinese Academy of Sciences in October 2021.
The first author: Liu Ailing, PhD students Ma Teng, Jin Hao, Xu Ning; Corresponding author: Researcher Sun Zhihong (Impact Factor: IF=7.
171)
.


Original link: https://doi.
org/10.
1128/Spectrum.
00859-21

---

　　As a common chronic inflammatory respiratory disease, asthma has a high morbidity and mortality rate worldwide.
It affects more than 330 million children and adults.
It is estimated that the number of patients will increase to 400 million by 2025
.
Recently, the potential impact of the human microbiota in the pathogenesis of asthma and its relationship with the disease phenotype has received special attention
.
Probiotics can regulate the host's intestinal microbiota and its synthesis/release of certain active compounds, and are often used as an adjuvant therapy
.
There is a clear connection between the exacerbation of asthma and the host microbiota, especially the gut microbiota, but how they affect asthma symptoms and serum metabolites is still largely unknown
.
Therefore, the purpose of this test is to study the auxiliary effect of probiotic combination drugs in the control of asthma
.


　　A total of 58 subjects were recruited in the study (29 in the probiotic group and 26 in the placebo group), and a randomized, double-blind, placebo-controlled method was used for a 6-month clinical trial
.
Subjects in the probiotic group used Symbic and Bifidobacterium lactis Probio-M8 (2g; 3x10 ¹⁰ CFU/day) daily, and the placebo group used Symbic and the same amount of placebo daily
.
The results found that during the intervention period, compared with placebo, subjects in the probiotic group had significantly lower alveolar nitric oxide concentration (CaNo) and exhaled nitric oxide concentration (FeNO), significantly improved asthma control (ACT) scores, and continued treatment After 3 months, the improvement effect was more significant; after 3 months of taking probiotics, the content of animal Bifidobacterium and Bifidobacterium longum in the intestines of subjects in the probiotic group increased significantly; the probiotic group had a higher diversity of microbiota (SGBs) are involved in the synthesis of butyric acid and the degradation of tryptophan.
The content of docosatetraenoic acid, lactoylethanolamide, and sphingomyelin in the intestine is significantly higher than that in the placebo group
.
Shows that Probio-M8 promotes specific biologically active metabolites and related pathways by regulating the intestinal flora
.
In addition, after 3 months of treatment, the intake of Probio-M8 significantly changed the serum metabolomics.
After the intervention of probiotics, the levels of metabolites such as dodecanoic acid, enterodiol, tryptophan and sphingomyelin in the blood increased significantly.
These metabolites can inhibit signal pathways to exert anti-inflammatory effects and participate in immune responses
.
In summary, Probio-M8 improves the bioactive metabolic potential of intestinal microbes and serum metabolites by regulating the intestinal flora, promotes the secretion and synthesis of some key biologically active compounds in the intestine and blood, and directly regulates the intestine through the systemic circulatory system- Lung axis, thereby effectively alleviating small airway inflammation and improving the clinical symptoms of asthma patients
.


　　The research was published in " Microbiology Spectrum ", a JCR area 2 magazine of the Chinese Academy of Sciences in October 2021.
The first author: Liu Ailing, PhD students Ma Teng, Jin Hao, Xu Ning; Corresponding author: Researcher Sun Zhihong (Impact Factor: IF=7.
171)
.


Original link: https://doi.
org/10.
1128/Spectrum.
00859-21 ¹⁰ Microbiology Spectrum https://doi.
org/10.
1128/Spectrum.
00859-21　　

---